DATA GRAPHICS | Product Development Retatrutide data strengthen Lillys hand in high-BMI obesity Phase III data put weight loss above CagriSemas benchmark, with tolerability that may be good enough to preserve a commercial edge May 21, 2026 7:09 PM UTC Lilly again has the frontrunner in the weight loss Olympics: its triple agonist retatrutide showed greater Phase III obesity efficacy than Novo Nordisks dual-acting CagriSema, with a tolerability profile that does not appear markedly worse
This unique formulation allows for precise dosing and may be more comfortable for those who struggle with injections
Freezing, cloudiness, visible particles, discolouration, or crystalline deposits are signs the product should not be used
Representative examples of chemical PEs that are being applied to various peptides and currently being studied include medium-chain fatty acids (MCFAs), Eligen technology-based PEs (SNAC, 5-CNAC, 4-CNAB), EDTA, bile salt, acyl carnitine, and alkylmaltoside
This represents substantial savings compared to US prices, which can exceed $250 per week without insurance coverage [9]